Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease November 10, 2023 by Leave a Comment Last Updated on November 10, 2023 by [#item_full_content] Share this:TwitterFacebookMorePrintLike this:Like Loading... Related Spread the word
Leave a Reply